{"id":"pneumococcal-20-valent-conjugate-vaccine","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT07086677","NCT00617760","NCT06531538","NCT05408429","NCT07019909","NCT05452941","NCT04382326","NCT04887948","NCT05512819","NCT06782282","NCT03835975","NCT04530838","NCT01272999","NCT03828617","NCT06524414","NCT06760208","NCT06622109","NCT06182124","NCT07160244","NCT04642079","NCT04546425","NCT05875727","NCT04875533","NCT03760146","NCT02787863"],"aliases":[],"patents":[],"pricing":[],"allNames":"pneumococcal 20-valent conjugate vaccine","offLabel":[],"timeline":[{"date":"2009","type":"neutral","milestone":"Phase 3 Initiated","description":"Phase 3 trial (Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With) — Neisseria Meningitidis (Bacterial Meningitis)"},{"date":"2016","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary ) — Chronic Obstructive Pulmonary Disease"},{"date":"2026","type":"neutral","milestone":"Phase 1 Initiated","description":"Phase 1 trial (A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults) — Pneumococcal Disease"},{"date":"2026","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (A Study to Learn About How a New Pneumococcal Vaccine Works in Children) — Pneumococcal Disease"}],"aiSummary":"The Pneumococcal 20-valent conjugate vaccine is a vaccine component that induces an immune response, classified as a biological vaccine. It is used to prevent pneumococcal infections, specifically those caused by Streptococcus pneumoniae, and is typically administered to adults aged 60 years and older.","brandName":"Pneumococcal 20-valent conjugate vaccine","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"Vaccine","drugClass":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be ","explanation":"Pneumococcal 20-valent conjugate vaccine works by introducing small pieces of 20 different pneumococcal bacteria strains into your body in a safe form. These bacterial components are attached to a carrier protein that acts like a signal flag, telling your immune system to pay attention. Your body then creates antibodies—specialized proteins—that can recognize these 20 pneumococcal types if you're ever exposed to the real bacteria.\n\nWhen you're later exposed to pneumococcal bacteria in real life, your pre-trained antibodies quickly identify and attack them before they can establish infection or spread through your bloodstream. This prevents both invasive infections (where bacteria enter the blood and organs) and pneumococcal pneumonia. The conjugate technology makes the vaccine particularly effective because it generates strong, lasting immune memory across different age groups.\n\nBy covering 20 strains instead of fewer types, this vaccine protects against a larger proportion of the pneumococcal bacteria circulating in the population, reducing overall disease risk for vaccinated individuals.","oneSentence":"For intramuscular use only. One dose (0.5 mL) of Pneumococcal 20-valent conjugate vaccine should be ","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"pneumococcal-20-valent-conjugate-vaccine","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Pneumococcal Immunization","phase":"preclinical","trialId":"","patients":null,"diseaseId":"vaccines","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07086677","phase":"Phase 1","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Adults","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":372,"indication":"Streptococcus Pneumoniae","completionDate":"2027-09","primaryEndpoint":"The purpose of this study is to learn about the safety and tolerability of a pneumococcal vaccine in adults."},{"nctId":"NCT00617760","phase":"Phase 3","title":"Safety and Immunogenicity Study of MenC-TT Vaccine (NeisVac-C) in Toddlers Previously Immunized With","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":330,"indication":"Neisseria Meningitidis (Bacterial Meningitis)","completionDate":"2009-08","primaryEndpoint":"The purpose of this study in healthy toddlers who have not previously been immunized against MenC infection and who completed their primary immunization series with PCV-7 (3 vaccinations) during infan"},{"nctId":"NCT06531538","phase":"Phase 2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":225,"indication":"Pneumococcal Disease","completionDate":"2026-02","primaryEndpoint":"The purpose of this study is to learn about the safety, tolerability and immune effects of a pneumococcal vaccine in toddlers."},{"nctId":"NCT05408429","phase":"Phase 3","title":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":356,"indication":"Pneumococcal Disease","completionDate":"2023-06","primaryEndpoint":"The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in toddlers who had 2 prior doses of Prevnar 13."},{"nctId":"NCT07019909","phase":"Phase 1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":400,"indication":"Pneumococcal Disease","completionDate":"2026-01","primaryEndpoint":"This Phase 1, randomized, double-blind, third-party-unblinded study will be conducted at investigational sites in China."},{"nctId":"NCT05452941","phase":"N/A","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":12500,"indication":"Pneumonia","completionDate":"2027-06","primaryEndpoint":"The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 ne"},{"nctId":"NCT04382326","phase":"Phase 3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healt","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1997,"indication":"Pneumococcal Disease","completionDate":"2022-09","primaryEndpoint":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants"},{"nctId":"NCT04887948","phase":"Phase 3","title":"Safety and Immunogenicity Study of 20vPnC When Coadministered With a Booster Dose of BNT162b2","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":570,"indication":"Pneumococcal Disease","completionDate":"2021-12","primaryEndpoint":"Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone"},{"nctId":"NCT05512819","phase":"Phase 3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":541,"indication":"Pneumococcal Disease","completionDate":"2025-09","primaryEndpoint":"The purpose of this study is to understand the safety and effects of a study vaccine (20vPnC) in infants and toddlers."},{"nctId":"NCT06782282","phase":"N/A","title":"A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Year","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":22234435,"indication":"Community-Acquired Pneumonia (CAP)","completionDate":"2026-10","primaryEndpoint":"The purpose of this study is to learn about how well the Prevnar 20 vaccine (PCV20) stops invasive pneumococcal disease (a group of severe infections caused by a bacteria called Streptococcus pneumoni"},{"nctId":"NCT03835975","phase":"Phase 3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Yea","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":875,"indication":"Pneumococcal Disease","completionDate":"2020-02","primaryEndpoint":"This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination"},{"nctId":"NCT04530838","phase":"Phase 3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":668,"indication":"Pneumococcal Disease","completionDate":"2022-04","primaryEndpoint":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants"},{"nctId":"NCT01272999","phase":"N/A","title":"Impact of Prevnar 13 on Ear Infections in Children","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":391,"indication":"Acute Otitis Media","completionDate":"2013-12","primaryEndpoint":"Prevnar (7 valent pneumococcal conjugate vaccine \\[7vPnC\\]) has been shown to be effective against ear infections in children."},{"nctId":"NCT03828617","phase":"Phase 3","title":"Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccin","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1710,"indication":"Pneumococcal Disease","completionDate":"2019-10","primaryEndpoint":"This is a Phase 3, randomized, double-blind study with a 4-arm parallel design."},{"nctId":"NCT06524414","phase":"Phase 2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Infants","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":605,"indication":"Pneumococcal Disease","completionDate":"2027-05","primaryEndpoint":"The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccine helps to fight against germs in infants when compared to the pneumococcal vacc"},{"nctId":"NCT06760208","phase":"N/A","title":"A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":660,"indication":"Pneumococcal Immunization","completionDate":"2027-03","primaryEndpoint":"The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market."},{"nctId":"NCT06622109","phase":"N/A","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":1100,"indication":"Pneumococcal Disease","completionDate":"2026-12","primaryEndpoint":"The purpose of this study is to learn about the safety of 20-valent Pneumococcal Conjugate Vaccine (PREVENAR 20) under actual clinical practice in Japan."},{"nctId":"NCT06182124","phase":"Phase 1/2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"Active Not Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":558,"indication":"Pneumococcal Disease","completionDate":"2026-05","primaryEndpoint":"The purpose of this study is to learn about the safety and immune effects of a pneumococcal vaccine in adults."},{"nctId":"NCT07160244","phase":"Phase 3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their ","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":6000,"indication":"Healthy","completionDate":"2028-11","primaryEndpoint":"BEATRIX (group B strEptococcus mATeRnal and Infant VaX study) The purpose of this study is to learn about the safety and how the group B streptococcus (GBS) vaccine works in pregnant women and their b"},{"nctId":"NCT04642079","phase":"Phase 3","title":"Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":839,"indication":"Pneumococcal Disease","completionDate":"2022-04","primaryEndpoint":"This study is designed to evaluate the safety and immunogenicity of 20vPnC in healthy children 15 months through 17 years of age"},{"nctId":"NCT04546425","phase":"Phase 3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healt","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1258,"indication":"Pneumococcal Disease","completionDate":"2022-04","primaryEndpoint":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants"},{"nctId":"NCT05875727","phase":"Phase 3","title":"A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":405,"indication":"Pneumococcal Disease","completionDate":"2023-10","primaryEndpoint":"The purpose of this study is to learn about the safety and immune response of 20vPnC in adults in India."},{"nctId":"NCT04875533","phase":"Phase 3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naï","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":1425,"indication":"Pneumococcal Disease","completionDate":"2022-05","primaryEndpoint":"A phase 3, randomized, double-blind trial to evaluate the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults 60 years of age and older in Japa"},{"nctId":"NCT03760146","phase":"Phase 3","title":"Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pne","status":"Completed","sponsor":"Pfizer","isPivotal":true,"enrollment":3902,"indication":"Pneumococcal Disease","completionDate":"2019-12","primaryEndpoint":"A Phase 3, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults"},{"nctId":"NCT02787863","phase":"Phase 4","title":"Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary ","status":"Completed","sponsor":"Mikhael Petrovich Kostinov","isPivotal":false,"enrollment":219,"indication":"Chronic Obstructive Pulmonary Disease","completionDate":"2016-12","primaryEndpoint":"Goal: to to examine the formation of postvaccination immunity and evaluate the therapeutic effect of bacterial vaccines in patients with inflammation diseases of bronchopulmonary system."}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"Vaccine","enrichmentLevel":3,"visitCount":4,"trialStats":{"total":2,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}